

Asier Benito-Vicente

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7972409/publications.pdf>

Version: 2024-02-01

27
papers

649
citations

623188

14
h-index

642321

23
g-index

27
all docs

27
docs citations

27
times ranked

833
citing authors

#	ARTICLE	IF	CITATIONS
1	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3426.	1.8	78
2	The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2113-2121.	1.8	71
3	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2248-2260.	1.1	60
4	Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. <i>Journal of Biological Chemistry</i> , 2018, 293, 7408-7422.	1.6	57
5	Functional Characterization and Classification of Frequent Low-Density Lipoprotein Receptor Variants. <i>Human Mutation</i> , 2015, 36, 129-141.	1.1	41
6	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. <i>Scientific Reports</i> , 2017, 7, 15282.	1.6	37
7	Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1676.	1.8	37
8	The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. <i>Genetics in Medicine</i> , 2015, 17, 980-988.	1.1	35
9	Characterization of the First PCSK9 Gain of Function Homozygote. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2152-2154.	1.2	30
10	Molecular mechanisms of lipotoxicity-induced pancreatic β -cell dysfunction. <i>International Review of Cell and Molecular Biology</i> , 2021, 359, 357-402.	1.6	28
11	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2018, 277, 448-456.	0.4	23
12	Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. <i>Scientific Reports</i> , 2020, 10, 1727.	1.6	23
13	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. <i>Atherosclerosis</i> , 2019, 289, 162-172.	0.4	21
14	Structural changes induced by acidic pH in human apolipoprotein B-100. <i>Scientific Reports</i> , 2016, 6, 36324.	1.6	14
15	miR-27b Modulates Insulin Signaling in Hepatocytes by Regulating Insulin Receptor Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8675.	1.8	14
16	The use of targeted exome sequencing in genetic diagnosis of young patients with severe hypercholesterolemia. <i>Scientific Reports</i> , 2016, 6, 36823.	1.6	13
17	Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. <i>Atherosclerosis</i> , 2017, 263, 163-170.	0.4	13
18	Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model. <i>Small</i> , 2022, 18, e2105915.	5.2	13

#	ARTICLE	IF	CITATIONS
19	Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition. <i>Biomedicines</i> , 2020, 8, 373.	1.4	11
20	MLb-LDLr. <i>JACC Basic To Translational Science</i> , 2021, 6, 815-827.	1.9	10
21	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13602.	1.8	10
22	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 934-943.	1.1	5
23	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. <i>Biomaterials Science</i> , 2021, 9, 3185-3208.	2.6	5
24	MLb-LDLr: LDLaren hartzaile aldaeren eragina auresateko ikasketa automatikoko eredu. , 0, , .		0
25	ACT toxina eta mintzeko kolesterolaren arteko elkarrekintzaren azterketa. , 0, , .		0
26	Nanopartikulen lipido konposizioak rHDLen kolesterol kanpora-fluxuaren efizientzia eragina du. , 0, , .		0
27	Familial hypercholesterolemia. , 2022, , 501-524.		0